Japan’s reimbursement process emphasizes balancing innovation with cost-effectiveness. MHLW evaluates clinical outcomes, cost-benefit ratios, & real-world performance to determine fair pricing. Health technology assessments (HTAs) are increasingly used to support this approach.
